Shire completes acquisition of Dyax

The addition of Kalbitor and DX-2930 to Shire's portfolio strengthens its leadership position in hereditary angioedema.

Shire’s Chief Executive Officer, Flemming Ornskov, commented: “We are excited to complete the acquisition of Dyax and look forward to working alongside their very talented and committed team to address significant unmet patient need around the world. The addition of Kalbitor and DX-2930 to our portfolio strengthens our leadership position in HAE and, along with the commercial and research and development expertise at Dyax, is a clear strategic fit for us that advances our position as the global leader in rare diseases. We are confident that our patients, particularly those with HAE, will be served for many years to come.”